Andy Kidd, Aptinyx CEO

Af­ter im­plod­ing three years ago, Aptinyx fol­lows a painful set­back with yet an­oth­er PhII fail­ure

More than three years af­ter Aptinyx shares $AP­TX were squashed by a mid-stage set­back for its lead drug, the biotech has un­veiled the bot­tom-line re­sults for a fol­low-up at­tempt to suc­ceed where it first failed bad­ly.

And it’s not pret­ty.

Pur­su­ing a 50 mg dose of NYX-2925 in a study of 229 pa­tients with ad­vanced painful di­a­bet­ic pe­riph­er­al neu­ropa­thy — where re­searchers found some cause for en­cour­age­ment in 2019 — did noth­ing to move the di­al in com­par­i­son to a place­bo. The biotech not­ed:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.